The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...

Experts, such as Lloyd Mulenga, M.Sc., M.B., Ch.B., Ph.D., discuss long-acting injectable HIV PrEP's potential in Zambia, ...

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Conference on HIV Science officially opened Monday in the Rwandan capital of Kigali, with a strong call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...

Scientists, researchers, policy makers and HIV/AIDS advocates at a meeting in Kigali, Rwanda, from July 13-17 for the 13th International AIDS Conference on HIV Science (IAS 2025), have raised an alarm ...

Global progress against AIDS is at risk as US funding cuts threaten life-saving programs. Experts warn of millions of ...

The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice ...